<DOC>
	<DOCNO>NCT00607750</DOCNO>
	<brief_summary>This study double-masked , randomize , placebo-controlled study safety preliminary efficacy ATG003 ( topical mecamylamine ) patient receive maintenance injection either ranibizumab bevacizumab . Study Hypothesis : Mecamylamine could effective treatment neovascular AMD .</brief_summary>
	<brief_title>Safety Efficacy ATG003 Patients With AMD Receiving Anti-VEGF</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Mecamylamine</mesh_term>
	<criteria>&gt; 55 year age clinical diagnosis neovascular AMD confound ocular condition</criteria>
	<gender>All</gender>
	<minimum_age>56 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Wet AMD , Comentis , ATG003 , mecamylamine</keyword>
</DOC>